NCT01174108View on ClinicalTrials.gov

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 10, 2010

Primary Completion Date

December 30, 2027

Study Completion Date

June 30, 2028

Conditions
Severe Aplastic AnemiaMDS (Myelodysplastic Syndrome)
Interventions
DEVICE

Miltenyi CD34 Reagent System

The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.

OTHER

Donor derived G-CSF mobilized PBC

Cell Therapy

Trial Locations (2)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

21201

COMPLETED

University of Maryland, Baltimore (UMB), Baltimore

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH